Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ADC Therapeutics SA

< Previous 1 2 3 Next >
ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, 2022
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Rituximab in First-Line Diffuse Large B-Cell Lymphoma
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics to Present at the Jefferies Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics Announces CEO Transition
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9, 2022
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for Medicare & Medicaid Services
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2021
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference Call on March 3, 2022
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics to Participate in Guggenheim Oncology Conference
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA®
From ADC Therapeutics SA
Via Business Wire
Tickers ADCT
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.